Company profile
Sera Prognostics, Inc.
NASDAQ: SERA · Healthcare · Medical - Diagnostics & Research
#1056 of 1,422 Healthcare companies by revenue49th-percentile growth
EA Score
41DFH 38DQ 48GM 34SS 45
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, filing timeliness · ↓ operating margin, net margin
Methodology →Revenue TTM
$70.0k
Rev growth YoY (TTM)
-35.2%
Net income (FY)
-$31.9M
Employees
72
as of 2026-08-18
Market cap
$77.5M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$81.0k$81.0k2025
Net income-$31.9M-$31.9M2025
Operating income-$36.5M-$36.5M2025
Total assets$101.9M$101.9M2025
Liabilities$26.5M$26.5M2025
Equity$75.4M$75.4M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Sera Prognostics, Inc.’s revenue?
Sera Prognostics, Inc. booked $81.0k in FY2025 revenue, growing 5.2% year over year — about the middle of the pack among Healthcare companies we track, at a -39417.3% net margin.
Peers · Healthcare
Zecotek Photonics Inc.——Black Bird Biotech, Inc.——U.S. Stem Cell, Inc.——Xebra Brands Ltd.——Imaging Dynamics Company Ltd.31DNemaura Medical Inc.——Neighbors
Salt Lake →Key facts
CEOZhenya Lindgardt
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersSalt Lake City, UT
ExchangeNASDAQ: SERA
Employees72
IPO date2021-07-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.